Johnson & Johnson (JNJ)

Amazon, Microsoft, JPMorgan Chase, Johnson & Johnson and Coca-Cola posted strong earnings beats that held up, with cloud growth, capital returns and raised guidance fueling sustained stock gains.

VYM, VCIT, and AGG offer low-cost ETF options for income investors, combining dividend yields between 2.20% and 4.86% with broad diversification and expense ratios as low as 0.03%.

The pharmaceutical icon's dividend yield has been pared back by the stock's recent rally, driven by a new growth initiative.

They are going through a rough patch, but it's too early to give up on them.

Intuitive Surgical is a leader in the surgical robotics space, with a large installed base and strong recurring revenues.

XLV's concentrated 60-stock portfolio beat VHT's broader 423 holdings over five years, though VHT delivered stronger 1-year returns.

Solventum shares gain on strong Q2 revenue, earnings, and cash flow, buybacks, and improved guidance, with analysts raising price targets amid a discounted valuation versus med/tech peers.

These healthcare giants can deliver steady gains.

Investors may want to brace for turbulence. But these stocks should hold up well.

As the NASDAQ-100 corrects amid an AI CapEx-driven tech sell-off, sectors like healthcare and financials are rallying, boosting diversified value ETFs like the Schwab U.S. Large-Cap Value ETF (SCHV).

Johnson & Johnson (NYSE:JNJ) outlined its commercialization plans for the OTTAVA robotic surgical system after receiving U.S. Food and Drug Administration De Novo authorization, positioning the table-integrated platform as a long-term growth initiative in surgical robotics. The company said it

As stocks pull back from recent highs, lean into these three blue chip dividend stocks.

They have a combined 181 years of consecutive payout increases.

Abbott trades at a cheaper valuation but carries higher litigation risk, while J&J boasts superior profitability despite a pending talc settlement.

Johnson & Johnson (NYSE: JNJ) shares are edging higher on Friday as investors digest two major biotech pipeline moves.

Things are going well for the pharmaceutical giant.